---
title: CRO Daily News — August 20, 2026
slug: daily-news-2026-08-20-cro
site: cro
post_kind: news
byline: BioBM
description: August 20 CRO daily: Revelation Biosciences Taps Avance Clinical for Phase 2/3 TITAN Study in Acute Kidney Injury — Avance Clinical secures a late-stage…
canonical_url: https://www.cro.directory/posts/daily-news-2026-08-20-cro
published_at: 2026-08-20T23:59:18.316Z
last_updated: 2026-08-21T00:00:03.510Z
---

### Revelation Biosciences Taps [Avance Clinical](/companies/avancecro) for Phase 2/3 TITAN Study in Acute Kidney Injury
- Revelation Biosciences selected [Avance Clinical](/companies/avancecro) to manage the Phase 2/3 adaptive TITAN study evaluating Gemini (TLR4 agonist) in acute kidney injury, targeting enrollment start in Q4 2026.
- Avance will provide full clinical trial support including site identification, patient recruitment, safety monitoring, and data management across approximately 300 hospital-based renal patients.
- The engagement leverages Avance's recently expanded Asia Pacific footprint and GlobalReady multi-regional delivery model to support the adaptive design registration study.

**Operational Impact**

[Avance Clinical](/companies/avancecro) secures a late-stage pivotal mandate for a U.S.-listed biotech sponsor, reinforcing its competitive position in adaptive Phase 2/3 registration studies and validating its expanded Asia Pacific clinical operations network.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cro-news/revelation-biosciences-selects-avance-clinical-as-cro-for-phase-2-3-titan-study-of-gemini-in-acute-kidney-injury)*

## References

1. [PharmaSource RSS — Revelation Biosciences Taps Avance Clinical for Phase 2/3 TITAN Study in Acute Kidney Injury](https://pharmasource.global/content/news/cro-news/revelation-biosciences-selects-avance-clinical-as-cro-for-phase-2-3-titan-study-of-gemini-in-acute-kidney-injury)

Source: https://www.cro.directory/posts/daily-news-2026-08-20-cro